If difficulties persist, please contact the System Administrator of this site and report the error below.位置： && 电子期刊 && 正文
铋盐类药物的研发及在Hp根除治疗中的应用
作者：&&&&&&&&&&&
单位：&&&&&
关键词：&&&&&&&&
分类号：R943.4
出版年,卷(期):页码):394-403
目的 使广大医务人员对铋盐类化合物药物的作用机制、临床应用、发展前景有一个深刻的理解和认识,使该类药物在胃肠疾病的治疗中发挥更大的作用。方法 在查阅大量国内外文献的基础上,对胃肠疾病的发病机制、临床常用药物及治疗方案、铋盐类化合物及联合用药方案,以及新的铋盐类药物的研发和在Hp根除治疗中的应用进行陈述。结果与结论 随着对胃肠疾病发病机制研究的深入,根除Hp的药物及治疗方案层出不穷,但由于Hp对抗生素的耐药菌株不断出现,导致抗生素三联、四联治疗的失败。铋盐类化合物是杀灭Hp的安全有效药物,新的铋盐类化合物及制剂不断研发并在临床上推广应用,在胃肠疾病的治疗中发挥了重要作用。
Objective To make medical staff deeply understand the mechanisms,clinical application and development prospects of bismuth salt compounds which can play a greater part in the treatment of gastrointestinal diseases.Methods On basis of reading lots of literatures,the mechanisms,the medicines and the treatment methods in the clinical application,the methods of bismuth salt compounds and drug combination and the development and the application in eradicating Hp of new bismuth salt compounds are summarized.Results and Conclusion With further research on the mechanisms of gastrointestinal diseases,the medicines and the treatment methods of eradicating Hp are more and more,But because Hp to drugresistant strains of antibiotics appears continuously,triple-therapies and quadruple-therapies of antibiotics fail.Bismuth salt compounds are safe and effective to eradicate Hp.New bismuth salt compounds and preparations are developed continuously and popularized in the clinical application and play an important part in the treatment of gastrointestinal diseases.
作者简介：
于学敏,研究员;Tel:;E-mail:
参考文献：
[1] 奇云.埋藏在肠胃中的诺贝尔奖[J].生物学教学,):9-9.
[2] 刘文忠主编.幽门螺旋杆菌研究进展[M]. 上海:上海科学技术出版社,.
[3] 任刚,蔡嵘,陈强.幽门螺旋杆菌致病机制研究进展[J].临床与实验病理学杂志,-340.
[4] 杨冬华,陈曼湖主编.消化系统病治疗学[M].北京:人民卫生出版社,.
[5] Corren P,Haenszel W,Cuello C,et al.A model for gastric cancerepidemiology[J]. Lancet,-60.
[6] Spponen P,Kekki M.Haopakoskij,et al.Gastris Cancer risk in chronic gastritis:shatistical calcualations of cross sec tionaldata[J].Int J Cancen,-177.
[7] W.Anwar,B.K.Armstrong,P.Correa,et al.Schistosomes,liver flukes and Helicabacter pylori.Early gastric.IARC momographs on the evaluation on carcinogenic naks to humans[M].Lyon:International Agency for Research on cancer,.
[8] Fiocca R,Lainetti O,Villani L,et al.High incidence of Helicobacter pytori colonization in Early gastric cancer and the passible relationship to carcinogehenesis[J].Eur J GastroenterolHepatol,1993,5(suppl 2):52-58.
[9] Eunogast,Stutg Group. Aninternational Assoaition between Helicobacter pylori in faction and gastric cancer[J].Lancet,9-1362.
[10] 萧树东主编.消化病新理论与新技术[M].上海:上海科技教育出版社,1 999:157-158.
[11] 胡伏莲.幽门螺旋杆菌耐药及其根除失败原因研究[J].临床医学,):340-341.
[12] Watanakc K,TanakaA,ImaseK.et al.Amoxicilin Resistance in Helicobacter pylori:studies from Tokyo,Japarn from 1985 to 2003[J].Helicobacter,-11.
[13] Van Doora LJ,Schneeberger PM,Nouhan N,et al.Imoportance of Helicobacter pylori CarA and Vach status for the eficacy of antibiotic treatment[J].Gut,-326.
[14] 成红,胡伏莲.北京地区幽门螺旋杆菌耐药情况及其耐药趋势[J]. 中华医学杂志,):.
[15] 胡伏莲,周殿元.幽门螺旋杆菌感染的基础与临床[M].修订版北京:中国科技出版社,2002.
[16] 宋文宣,李杨,孙玉安,等.实用内科药物治疗学[M].北京:人民卫生出版社,59.
[17] Mohamed AH,Hunt RH.The rationale of acid suppression in thetreatment of acid-relaed disease Aliment Pharmacol[J].Therap,1994,8(suppl 1):3-4.
[18] 徐淑云主编.中华临床药物学(下册)[M].北京:人民卫生出版社,.
[19] Warren JR,Marchall DY.Unidentified earved bacillon gastrieepithelium in actine Chronic gastritis[J].Lancet,3-1275.
[20] Sloniang BL,Kasinathan C,Murty VL,et al. Lypolytic activity of campylabacatel bismicth Subcitrte[J]. Am J Gastroenterd,3～1274.
[21] 北京大学医学教材.内科学[M].北京:北京大学出版社,1990.
[22] 于学敏,王振南,李彦英.维敏胶囊各项试验研究结论概述[J].中国新药杂志,):34-36.
[23] 周尔凤,于学敏,王振南,等.维敏胶囊主要药效学试验研究[J].中国新药杂志,1 993,2(3):36-37.
[24] 郭文栋,王大骏,闫柱,等.维敏胶囊治疗消化性溃疡的多中心临床研究[J].中国新药杂志,2(3):38-39.
[25] 郭文栋,姚汉武,师水生,等.维敏胶囊对慢性胃炎疗效的初步观察[J].中国新药杂志,2(3):40-41.
[26] 中华人民共和国卫生部.胶态果胶铋新药证书[Z].卫药证字X-61号,1992.
[27] 中华人民共和国卫生部.胶态果胶铋胶囊新药证书[Z].卫药证字X-62号,1992.
[28] 中华人民共和国专利局.胶态果胶铋药物及制造方法、发明专利证书[P].专利号:ZL ,1998.
[29] 中华人民共和国专利局.胶态酒石酸药物及制造方法、发明专利证书[P].专利号:ZL ,1996.
[30] 中华人民共和国知识产权局.一种胶体酒石酸药物及制备方法和用途、发明专利证书[P].专利号:.X,2011.
[31] 中华人民共和国卫生部.胶体酒石酸铋新药证书[Z].1993.
[32] 中华人民共和国卫生部.胶体洒石酸铋胶囊新药证书[Z].1993.
[33] 周尔凤,王振南,龙平,等.胶体酒石酸铋胶囊主要药学试验研究[J].中国新药杂志,):45-47.
[34] 郭文栋,王大骏,肖晋美,等.胶体洒石酸铋胶囊治疗胃肠疾病的临床验证[J].中国新药杂志,):48-50.
[35] Freston JW. Hclicobacter pylori,acid,gastritis,atrophy and progression to cancer:a critical wiew.In:Hant RH,Tytgat GNJ,ed,Helicobacter pylori:Basic mechanisms to clinical care 1996,Lancaster[M].Kluwer Academic Publishers,.
[36] Knipers EJ,Lundell L,klinkenberg knol EC,et al.A trophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treted with omeprazole or fundophication[J].NEngl J Med,8-1022.
[37] Axon ATR.The ascorbic acid story.In.Hunt RH,Tytgat GNJ,ed,Helicobactar pylori:Basic mesic mechanisms to chnical cure[M].Dordrecht.Boston,London:Kluwer Academic publishers,.
[38] Moss SF,Calam J,Agarwal B,et al.Indaction of gastric epithelial apoptosis by Helicobacter pylori[J].Gut,-501.
[39] Fan XG,Kelleher D,Fan XJ.Helicobacter pylon increase proliferation of gastric epithelial cells[J].Gut,-20.
[40] Mutsumoto S,Washizuka Y,Matsumoto Y,et al.Indication of ulceration and severe gastritis in Mongolian gerbil by Helicobacter pylori infection[J].Journal of Medical Microbiology,-397.
[41] EI kaissouni-J,Bene-MCFaure-GC.Activation of epithelial cells in gastritis[J].Digestion,):53-59.
[42] Ko-GH,Park HB.Monaclonal antibodies against Helicobacter pylori Lross react with human tissve[J].Helicobactre,):210-215.
[43] Gillen D,EI omar EM,Wirz AA,et al.The acid responseto gastrin distingui shes duodenal ulcer patientis from Helicobacter pylori-infected healitry subjects[J].Gastroen terology,-57.
[44] Enerhard JE.Recent devlapments in the epidemiology of Heliobacter pylori[J].Gastroenterol Clin N Am,-560.
[45] Peterson WL,Fendrick AM,Cave DR,et al.Helicobacten pylori related diseaae:guidclincs for testing and treatment[J].Arch Intern Med,):.
[46] Lindberg P,Keeling D,Fryklund J,et al.Esomeprazole enhanced bioavailability,spocifcity for the proton pump and inhibition of acid secertion[J].Aliment plrmacol Ther,):481-488.
[47] Vander hulst RWM,Koller J J,Rauws GHJ.Treatment of Hp infection in humans:A review of the world literatwre[J].Helicobacterr,-19.
[48] 肃树东,郑青.Hp治疗指征及国内外的推荐治疗方案[J].中华消化杂志,):555-556.
[49] 张万岱,徐智民.Hp耐药的验证[J].中华消化杂志,):558-557.
[50] 成红,胡伏莲.Hp耐药机制[J].中华消化杂志,):558-559.
[51] 史彤,刘文忠,肃树东,等.上海地区幽门螺旋杆菌耐药率的变迁[J].中华消化杂志,):576-578.
[52] Watanabe K,Tanaka A,Imasek,et al.Amoxicillin Resistance in Helicobacer pylori:Studies from Tokyo,Japan from 1985 to 2003[J].Helicobacer,):4-11.
[53] Broutet N,Tchamgoue S,Pereira E,et al.Risk factors for failure of Helicobacter pylori therapy-resulis of an individual data analy sis of 2751 patients[J].Aliment pharmacol Ther,-109.
[54] Masaaki Minami,Takafumi Ando,shin-nosuke Hashikaw,et al.Efect of Glycine on Helicobacter pylori In Vitro.Antimerob Agents Chemocherapy[J]. Antimicrob Agents Chemacherapy,):.
[55] Quesada M,Sanfeliu I,Junquera F,et al.Evaluation of Hclicobacter Pylori suscepribility to rifaximin[J].Gastventerol Hepatol,):393-396.
[56] Misiewica JJ.The Sydney system.A new classification of gastris[J].J Gastroenterol Hepatol,):207-208.
[57] 王爱军,赵俊积,米庆霞.奥美拉唑与胶体果胶铋根除幽门螺旋杆菌感染80例临床观察[J].中国现代医院杂志,):113-115.
[58] 张昊,于静,贾长河.用三联疗法根除幽门螺旋杆菌失败后的补救方案[J].Chin clin Pea macol,):361-362.
[59] 冯淑芳,李明泉.果胶铋四联疗法和三联疗法治疗幽门螺旋杆菌阳性十二指肠溃疡病[J].医学专业半月刊,):40-41.
[60] Harfod W,Lanza F,Arora A,et al.Double-blind,multicenter evaluation of lansoprazole and amoaxicillin pytori infacton[J].Helicobacter,-250.
[61] Wng JJY,Chan FKL,Wu JCY,et al.Ope waek ranitidine bismuth cicrite in conbinations with meronida zole,amoxycillin and clarithromycin in the treatment of Helicobacter pylori faction:the RBCMACH study[J].Aliment phamacol Ther,):.
[62] BCY Wang,WM Wong,SK Lam,et al.One-week ranitidine bisnmuth citrate based triple therapy fo the eradication of Helicobaeter in long kong with high prevalence of metron idazale resistance[J].Aliment pharmacol Ther,-409.
[63] Borody TJ,Andrews P,Fracchia G,etal.Omeprazole enhances efficy of tripk thersapg in eradicating Helicobacter pylori[J].Gut,-481.
[64] De boer W,Dricasen W,Janaz A,et al.Effect of acidsuppre sion on.Efficacy of treatment for Helicobacter pylori infection[J].Laneet,-820.
[65] 中华人民共和国知识产权局.发明专利证书、专利名称:纳米胶体果胶铋及其颗粒剂药物[P].专利号:ZL. 3,2010.
服务与反馈：
主办单位：《中国药事》编辑部&&&&&&&&&备案号：京ICP备号-1
地址：北京市东城区天坛西里2号& 中国食品药品检定研究院& 《中国药事》编辑部&&&&&&&& &邮政编码：100050&&&&&&&& &电话：010-&&&&& 电子邮件：
技术服务电话：010-&&&&&&&&&&(window.slotbydup=window.slotbydup || []).push({
id: '2014386',
container: s,
size: '234,60',
display: 'inlay-fix'
&&|&&0次下载&&|&&总42页&&|
您的计算机尚未安装Flash，点击安装&
阅读已结束，如需下载到电脑，请使用积分（）
下载：20积分
0人评价21页
0人评价2页
0人评价5页
0人评价26页
0人评价4页
0人评价67页
所需积分：（友情提示：所有文档均可免费全文预览！下载之前请务必先预览阅读，以免误下载造成积分浪费！）
（多个标签用逗号分隔）
文不对题，内容与标题介绍不符
广告内容或内容过于简单
文档乱码或无法正常显示
若此文档涉嫌侵害了您的权利，请参照说明。
评价文档：
下载：20积分 上传我的文档
 下载
 收藏
该文档贡献者很忙，什么也没留下。
 下载此文档
正在努力加载中...
2014年12月美国FDA批准的新药和通用名药
下载积分：866
内容提示：2014年12月美国FDA批准的新药和通用名药
文档格式：PDF|
浏览次数：19|
上传日期： 19:09:46|
文档星级：
该用户还上传了这些文档
2014年12月美国FDA批准的新药和通用名药
官方公共微信}